Novavax scores narrower Covid vaccine approval
Digest more
The FDA finally approved Novavax's Covid-19 vaccine, but placed restrictions on it that its two competitors in the U.S. do not face
The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots. Moderna (MRNA) and Pfizer (PFE) shares move higher on this news, while Novavax (NVAX) takes a dip.
The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination trends.
Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is soaring after the company's COVID-19 vaccine was approved by the US Food and Drug Administration (FDA).
JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,
Explore more
Tesla's Chinese rival Xiaomi announced its electric SUV set to compete with Tesla's Model Y will be launched Thursday. TXNM Energy agreed to be purchased by Blackstone's infrastructure division for $11.5 billion in cash and debt.